Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 1

1(25.0%)

4Total

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05520476Active Not Recruiting

Neuroliten MVP System Clinical Observation Study

Role: collaborator

NCT05732610Not ApplicableCompleted

MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study

Role: collaborator

NCT05334758Not ApplicableCompleted

Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test

Role: collaborator

NCT05213897Completed

Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings

Role: collaborator

NCT05172154Completed

GlowTest COVID-19 Antigen Home Test Kit Usability Study

Role: collaborator

NCT05140005Not ApplicableCompleted

GlowTest COVID-19 Antigen Home Test Kit QRI Use Study

Role: collaborator

NCT04161482Phase 1Completed

An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

Role: collaborator

All 7 trials loaded